csirt@kutim:~/threat-intel/cve/CVE-2023-49657

Katalog CVE

CVSS 5.4 · Medium EPSS 0,84%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') pada apache superset. Skor CVSS 3.1 5.4 (Medium) menurut NVD.

Deskripsi (NVD)

A stored cross-site scripting (XSS) vulnerability exists in Apache Superset before 3.0.3. An authenticated attacker with create/update permissions on charts or dashboards could store a script or add a specific HTML snippet that would act as a stored XSS. For 2.X versions, users should change their config to include: TALISMAN_CONFIG = {     "content_security_policy": {         "base-uri": ["'self'"],         "default-src": ["'self'"],         "img-src": ["'self'", "blob:", "data:"],         "worker-src": ["'self'", "blob:"],         "connect-src": [             "'self'",             " https://api.mapbox.com" https://api.mapbox.com" ;,             " https://events.mapbox.com" https://events.mapbox.com" ;,         ],         "object-src": "'none'",         "style-src": [             "'self'",             "'unsafe-inline'",         ],         "script-src": ["'self'", "'strict-dynamic'"],     },     "content_security_policy_nonce_in": ["script-src"],     "force_https": False,     "session_cookie_secure": False, }

Rincian

Terbit di NVD
23 Januari 2024
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
5.4 (Medium), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
EPSS (30 hari)
0,84% peluang dieksploitasi; lebih tinggi dari 56,6% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
apache superset Semua versi sebelum 3.0.3

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.